A research group has developed a CAR targeting EphA2 to investigate its efficacy in both in vitro flow cytometry and real-time cell electronic sensing system assays, and in vivo in a mouse model of NSCLC. The gene discussed is EPHA2; the disease is non-small cell lung carcinoma.